STOPPAM
Strategies TO Prevent Pregnancy-Associated Malaria
| Coordinatore | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
Organization address
address: Boulevard de Dunkerque - CS 90009 44 contact info |
| Nazionalità Coordinatore | France [FR] |
| Totale costo | 3˙935˙026 € |
| EC contributo | 2˙997˙918 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-02-01 - 2011-07-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
Organization address
address: Boulevard de Dunkerque - CS 90009 44 contact info |
FR (MARSEILLE) | coordinator | 0.00 |
| 2 |
ALMA CONSULTING GROUP SAS
Organization address
address: Domaine des Bois d'Houlbec contact info |
FR (HOULBEC COCHEREL) | participant | 0.00 |
| 3 | KOBENHAVNS UNIVERSITET | DK | participant | 0.00 |
| 4 |
NATIONAL INSTITUTE FOR MEDICAL RESEARCH
Organization address
address: Ocean Road - Luthuli Street 2488 contact info |
TZ (DAR ES SALAAM) | participant | 0.00 |
| 5 |
STICHTING KATHOLIEKE UNIVERSITEIT
Organization address
address: GEERT GROOTEPLEIN NOORD 9 contact info |
NL (NIJMEGEN) | participant | 0.00 |
| 6 |
STOCKHOLMS UNIVERSITET
Organization address
address: Universitetsvaegen 10 contact info |
SE (STOCKHOLM) | participant | 0.00 |
| 7 |
UNIVERSITE D ABOMEY CALAVI UAC
Organization address
address: CAMPUS UNIVERSITAIRES D ABOMEY contact info |
BJ (ABOMEY CALAVI) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The Partners propose to conduct a cohort study in pregnant women and their newborns to quantify the effects of Pregnancy-Associated Malaria (PAM) and to identify a PAM vaccine candidate. Effects of PAM on the pregnant woman (placental infection and anaemia), the offspring (birth weight reduction), and the infant (increased morbidity and mortality) are well known. Studies underlined the role of P. falciparum variable surface antigens expressed on infected erythrocytes in binding to placenta. A specific immune response against this antigen reduces the effect of PAM during latter pregnancies, making possible to develop a new preventive strategy based on the enhancement of this specific response. This goal will be achieved through cohort studies in 2 endemic areas (West and East Africa), as the mechanisms and the resulting effects may vary with transmission. Biological samples will be collected during pregnancy and infancy to dissect the pathological and immune mechanisms involved, as well as to characterize phenotypically and genetically the infecting parasites, providing a structural basis for anti-PAM vaccine design. The immunopathological effects will be measured in the mothers, their newborns, and the infant, in relation with timing of infection. The ultimate goal is to identify the most immunogenic epitopes of VAR2CSA (the major variable surface antigens of P. falciparum parasites infecting the pregnant women) to be included in such a vaccine. It is anticipated that the product of this project will be directly usable to enter in the pipeline of vaccine development. The 7 Partners of the consortium (5 from 4 EU countries, and 2 from Benin and Tanzania) have a combined history of high class, internationally-recognized research in malaria. All EU teams have huge experience of collaboration with malaria endemic countries institutions and with studies related to malaria in pregnant women, that are also routinely conducted by the 2 African Partners.'